- Home
- NVS
NVS
Novartis AG
as 08-29-2025 4:00pm EST
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
| Founded: | 1895 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 242.8B | IPO Year: | 1991 |
| Target Price: | $123.67 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Hold | Number of Analysts: | 6 |
| Dividend Yield: | Dividend Payout Frequency: | Annual | |
| EPS: | 6.85 | EPS Growth: | -12.59 |
| 52 Week Low/High: | $96.06 - $128.03 | Next Earning Date: | 10-28-2025 |
| Revenue: | $55,186,000,000 | Revenue Growth: | 12.95% |
| Revenue Growth (this year): | 9.01% | Revenue Growth (next year): | 2.49% |
Latest Novartis AG News
NVS Breaking Stock News: Dive into NVS Ticker-Specific Updates for Smart Investing
Simply Wall St.
16 hours ago
The Bull Case For Legend Biotech (LEGN) Could Change Following Appointment of CFO With Global Pharma Expertise
PR Newswire
2 days ago
Gateway to Growth: Innovation and Opportunity at the 8th CIIE
Clinical Trials Arena
2 days ago
Eli Lilly’s Verzenio boosts OS in breast cancer as Novartis rivalry heats up
Zacks
3 days ago
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
GlobeNewswire
4 days ago
Binge Eating Disorders Global Market Research Report 2025-2035 Featuring Eli Lilly, Amneal, Takeda, Tryp Therapeutics, Tonix, Sumitomo, VIVUS, Novartis, and Pfize
BioPharma Dive
4 days ago
Amylyx drug comes up short; Sanofi names new CMO
GlobeNewswire
4 days ago
HER2+ Breast Cancer Clinical Trials Analysis Report 2025 - Enhance Your Understanding of Trial Counts and Enrollment Trends Across G7 & E7 Countries
GlobeNewswire
4 days ago
Dyslipidemia Market Research Report 2025-2035 | Competitive Analysis of Amgen, Sanofi, Regeneron, Pfizer, Novartis, Viatris, AbbVie, AstraZeneca, Horizon Therapeutics, Esperion Therapeutic
Compare NVS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVS Novartis AG - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.